Numis Securities upgraded shares of Abcam (LON:ABC) to an add rating in a research report report published on Tuesday. The brokerage currently has GBX 1,340 ($17.51) price target on the stock.

ABC has been the topic of a number of other reports. JPMorgan Chase & Co. reissued a neutral rating on shares of Abcam in a report on Wednesday, January 2nd. Peel Hunt reissued a hold rating on shares of Abcam in a report on Thursday, December 6th. Finally, Berenberg Bank reissued a buy rating and set a GBX 1,640 ($21.43) target price on shares of Abcam in a report on Tuesday.

Shares of LON:ABC opened at GBX 1,228.19 ($16.05) on Tuesday. Abcam has a 1-year low of GBX 9.73 ($0.13) and a 1-year high of GBX 1,290 ($16.86).

In other news, insider Jonathan Simon Milner purchased 187,790 shares of the stock in a transaction dated Thursday, December 6th. The stock was acquired at an average price of GBX 1,060 ($13.85) per share, for a total transaction of £1,990,574 ($2,601,037.50). Also, insider Suzanne Smith purchased 864 shares of the stock in a transaction dated Wednesday, November 7th. The shares were purchased at an average price of GBX 1,219 ($15.93) per share, with a total value of £10,532.16 ($13,762.13).

About Abcam

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Featured Article: Dividend Aristocrat Index

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with's FREE daily email newsletter.